Bullish momentum fades — GSK trades around GBX 1,783 after intraday selling pressure

Traders Union
All News
Financial News
GSK slides 0.61% today to GBX 1,783

Highlights

GSK repurchased 180,000 ordinary shares at a volume-weighted average price of GBX 1,766.33, raising total buybacks in this program to 10,138,000 shares.
GSK now holds 235,602,844 shares in treasury out of 4,079,829,083 total issued shares following the latest buyback activity.
Recent performance shows GSK achieved a 41.52% return on equity, $3.75 billion in free cash flow, and currently yields a 3.58% dividend with a 47.37% payout ratio.

Share buyback expansion and strong cash flow drive equity returns

GSK has expanded its ongoing share buyback program by repurchasing 180,000 ordinary shares at a volume-weighted average price of GBX 1,766.33, now holding 235,602,844 shares in treasury out of 4,079,829,083 issued shares. The total number of shares repurchased since the initiation of this buyback has reached 10,138,000. Recent performance metrics also reflect a robust return on equity of 41.52% and free cash flow of approximately $3.75 billion, alongside a current dividend yield of 3.58% with a 47.37% payout ratio.

Positive momentum persists as overbought signals emerge and sellers test lows

Momentum remains positive, with D1 MACD signaling a strong buy and ADX at 26.19 reflecting a moderate uptrend. RSI D1 sits at 61.73, placing it in the bullish zone, while both Stoch RSI and CCI are neutral, suggesting no clear overbought or oversold conditions. The Bull/Bear Power (BBP) indicator is overbought, indicating continued buyer dominance intraday, but sellers are applying pressure after the open, with the price trading near today's low within a range of GBX 1,778.00–1,797.50. The MA-50 (GBX 1,661.10) serves as substantial support if the trend weakens, and the Ichimoku Kijun (GBX 1,713.25) acts as dynamic support, with momentum indicators mostly positive but overbought signals and a reversal from highs introducing some divergence.

Sideways bias prevails while upside breakout risk remains elevated

For the next five trading days, GSK is expected to trade within a range of GBX 1,760–1,900, reflecting typical volatility. The probability of an upward move exceeds 80%, with further declines appearing less likely. The baseline scenario is sideways trading between GBX 1,760 and GBX 1,870, but clearance of resistance near GBX 1,800 could trigger a run toward GBX 1,900. If support at MA-20 or the Ichimoku Kijun (GBX 1,778–1,713) fails, a correction toward GBX 1,760 may occur, though deeper losses seem unlikely due to strong trend signals on the D1 and W1 timeframes.

Anton Kharitonov, Traders Union expert, sees GSK maintaining a short-term bullish structure but notes rising overbought signals on key momentum indicators. He believes strong fundamentals and the ongoing buyback offer a cushion, yet technical risk remains if GBX 1,778–1,713 support breaks. Base case is a sideways move inside GBX 1,760–1,870, with any push above resistance triggering a test of GBX 1,900. "With momentum stretched and resistance near, I remain cautious and will only reassess bullish scenarios if MA-20 support holds convincingly."

Previously it was noted that GSK continued its share buyback activity and established a new partnership to advance tuberculosis treatment. The technical outlook described overbought momentum alongside robust trend based on market indicators.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.